We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.33%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
+$233M
(+9%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
4.64%
Top 10 Holdings %
Top 10 Hldgs %
38.82%
Holding
108
New
54
Increased
16
Reduced
13
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$123M |
| 2 |
Incyte
INCY
|
+$96M |
| 3 |
Encompass Health
EHC
|
+$82.4M |
| 4 |
Petco
WOOF
|
+$73.5M |
| 5 |
Zoetis
ZTS
|
+$66.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$100M |
| 2 |
Cooper Companies
COO
|
+$88.2M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$86.9M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$81.7M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$80.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.85% |
| 2 | Real Estate | 4.52% |
| 3 | Consumer Discretionary | 2.42% |
| 4 | Financials | 1.56% |
| 5 | Technology | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $159M | 5.62% |
1,725,650
-392,440
| -19% | -$33.1M |
|
2
Vertex Pharmaceuticals
VRTX
$122B
| $143M | 5.07% |
666,460
+83,170
| +14% | +$18.3M |
|
3
Zimmer Biomet
ZBH
$18.4B
| $122M | 4.3% |
782,470
+214,544
| +38% | +$33.2M |
|
|
4
Danaher
DHR
$138B
| $121M | 4.27% |
+604,236
| New | +$123M |
|
5
Humana
HUM
$44B
| $105M | 3.73% |
251,390
+31,209
| +14% | +$12.5M |
|
6
Medtronic
MDT
$110B
| $94M | 3.33% |
796,110
+191,960
| +32% | +$22.5M |
|
|
7
Incyte
INCY
$24.9B
| $93M | 3.29% |
1,144,287
+1,124,757
| +5,759% | +$96M |
|
8
McKesson
MCK
$101B
| $92.3M | 3.27% |
473,330
+50,530
| +12% | +$9.22M |
|
9
Maravai LifeSciences
MRVI
$996M
| $86M | 3.04% |
2,412,712
-722,000
| -23% | -$23.9M |
|
|
10
Encompass Health
EHC
$11B
| $82.3M | 2.91% |
+1,263,682
| New | +$82.4M |
|
11
Agios Pharmaceuticals
AGIO
$1.95B
| $79.2M | 2.8% |
1,532,960
+535,890
| +54% | +$26.5M |
|
12
AbbVie
ABBV
$455B
| $78.9M | 2.79% |
729,420
-124,230
| -15% | -$13.3M |
|
13
HCA Healthcare
HCA
$85.7B
| $78.2M | 2.77% |
414,990
-296,250
| -42% | -$52.2M |
|
14
IQVIA
IQV
$39.1B
| $77.6M | 2.74% |
401,690
-401,620
| -50% | -$75.4M |
|
15
Cencora
COR
$60.7B
| $68.9M | 2.44% |
+583,290
| New | +$63.1M |
|
|
16
Petco
WOOF
$794M
| $68.4M | 2.42% |
+3,088,000
| New | +$73.5M |
|
|
17
Zoetis
ZTS
$31.9B
| $66.4M | 2.35% |
+421,860
| New | +$66.8M |
|
18
Welltower
WELL
$170B
| $66.4M | 2.35% |
927,040
+569,920
| +160% | +$38.3M |
|
19
Ventas
VTR
$44.7B
| $61.3M | 2.17% |
1,149,860
+491,510
| +75% | +$25.2M |
|
20
Envista
NVST
$4.52B
| $58.6M | 2.07% |
1,435,370
+396,080
| +38% | +$15.1M |
|
21
DexCom
DXCM
$28.8B
| $51.1M | 1.81% |
+568,440
| New | +$53.4M |
|
22
BioCryst Pharmaceuticals
BCRX
$2.35B
| $49.7M | 1.76% |
+4,886,440
| New | +$50.4M |
|
23
Boston Scientific
BSX
$68.4B
| $45.4M | 1.61% |
+1,174,820
| New | +$44.5M |
|
|
24
Cooper Companies
COO
$14.2B
| $43.5M | 1.54% |
452,668
-929,852
| -67% | -$88.2M |
|
25
Qiagen
QGEN
$8.55B
| $40.8M | 1.44% |
+790,671
| New | +$43.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2021 Portfolio in Review
As of Q1 2021, HealthCor Management held 108 positions worth $2.83B, up 9% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
HealthCor Management deployed $131M of net new capital in Q1 2021, opening 54 new positions and adding to 16 existing holdings. Its largest new stake was Danaher: 604,236 shares worth $121M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 92% a quarter earlier, followed by Real Estate and Consumer Discretionary.
On the sell side, the largest reduction was Cooper Companies, an estimated $88.2M trimmed.
- HealthCor Management's largest Q1 2021 buy was Danaher: 604,236 shares worth $121M.
- HealthCor Management added most to Incyte in Q1 2021, an estimated $96M increase.
- HealthCor Management's biggest Q1 2021 reduction was Cooper Companies, cutting an estimated $88.2M.
- HealthCor Management fully exited Madrigal Pharmaceuticals in Q1 2021, selling an estimated $100M.
- HealthCor Management's ten largest holdings make up 39% of its $2.83B portfolio in Q1 2021.
- HealthCor Management opened 54 new positions and closed 25 in Q1 2021.
- HealthCor Management's portfolio value rose 9% quarter-over-quarter to $2.83B.
Based on HealthCor Management's 13F filing for Q1 2021, filed 17 May 2021.